Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005-2019.
Prim Care Diabetes
; 18(5): 561-563, 2024 10.
Article
em En
| MEDLINE
| ID: mdl-39095227
ABSTRACT
BACKGROUND:
The newer glucose-lowering drugs (GLDs), including Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), have demonstrated superior cardio- and renal protective benefits compared to older GLDs in individuals with type 2 diabetes (T2D) at high risk for cardiovascular disease (CVD).OBJECTIVE:
This study examined the trends of the newer GLDs use in people with T2D who had a history of coronary heart disease or heart failure in the United States.METHOD:
We used 2005-2019 data from the Medical Expenditure Panel Survey (MEPS). Individuals with self-reported diabetes and CVD history were identified.RESULTS:
There was a steady increase in the use of GLP-1RA only from 2008 (3â¯%) to 2019 (21â¯%) and SGLT2i only from 2014 (5â¯%) to 2019 (12â¯%). Individuals with dual use of both newer GLD classes increased from 0.62â¯% in 2015 to 6â¯% in 2019. The overall uptake of these two newer drugs in 2019 was less than 40â¯%. In other words, 60â¯% of individuals who can substantially benefit from these newer treatments did not use the treatments.CONCLUSION:
The use of GLP-1RA and SGLT2i among individuals with T2D and a history of CVD was low and varied by insurance type. Policy-level interventions are needed to improve the use of these newer treatments further.SUMMARY:
We examined how newer glucose-lowering drugs are used among individuals with type 2 diabetes and at high risk for coronary heart disease or heart failure in the US. We found that 60â¯% of individuals who can substantially benefit from these newer treatments did not use the treatments due to the variation of insurance type.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Padrões de Prática Médica
/
Doença das Coronárias
/
Diabetes Mellitus Tipo 2
/
Receptor do Peptídeo Semelhante ao Glucagon 1
/
Inibidores do Transportador 2 de Sódio-Glicose
/
Insuficiência Cardíaca
/
Hipoglicemiantes
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article